Format

Send to:

Choose Destination
See comment in PubMed Commons below
JAMA. 1994 May 25;271(20):1587-92.

Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators.

[No authors listed]

Abstract

OBJECTIVE:

To assess prospectively the impact on survival and health-related quality of life of two follow-up protocols in patients with early breast cancer.

DESIGN:

Randomized controlled clinical trial.

SETTING:

Multicenter study involving 26 general hospitals in Italy.

PATIENTS:

A consecutive sample of 1320 women younger than 70 years with stage I, II, and III unilateral primary breast cancer.

INTERVENTION:

Patients were randomly assigned to an intensive surveillance, which included physician visits and performance of bone scan, liver echography, chest roentgenography, and laboratory tests at predefined intervals (n = 655), or to a control regimen (n = 665), in which patients were seen by their physicians at the same frequency but only clinically indicated tests were performed. Both groups received a yearly mammogram aimed at detecting contralateral breast cancer.

MAIN OUTCOME MEASURES:

Primary end points were overall survival and health-related quality of life.

RESULTS:

Compliance to the two follow-up protocols was more than 80%. At a median follow-up of 71 months, no difference was apparent in overall survival with 132 deaths (20%) in the intensive group and 122 deaths (18%) in the control group. No significant differences were apparent in time to detection of recurrence between the two groups. Measurements of health-related quality of life (ie, overall health and quality-of-life perception, emotional well-being, body image, social functioning, symptoms, and satisfaction with care) at 6, 12, 24, and 60 months of follow-up did not show differences by type of care received.

CONCLUSIONS:

Results of this trial support the view that a protocol of frequent laboratory tests and roentgenography after primary treatment for breast cancer does not improve survival or influence health-related quality of life. Routine use of these tests should be discouraged.

PMID:
8182811
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Write to the Help Desk